US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

Frontiers SNS-032 attenuates liver fibrosis by anti-active

Our Anti-Arl13b mouse monoclonal primary antibody from NeuroMab is produced in-house from hybridoma clone N295B/66. It is KO validated, detects human,

Anti-Arl13b Antibody

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

In vivo production of CAR-T cells using CD5/LNP-FAPCAR

Frontiers Nanotechnology in Drug Delivery for Liver Fibrosis

CD352 (NTB-A) Antibody, anti-human, REAfinity™

CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated

Anti-Arl13b Antibody (N295B/66) from NeuroMab Official Supplier

University of pennsylvaniaPatents

University of pennsylvaniaPatents

CD63 Antibody (MX-49.129.5) SCBT - Santa Cruz Biotechnology

WO2015183842A1 - Methods and compositions for preventing ischemia

Efficient drug and gene delivery to liver fibrosis: rationale

US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5

T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR